Vaxart (VXRT) Osake Kurssi
Vaxart Kurssi
Viimeisten 19 vuoden aikana Vaxartn liikevaihto kasvoi 5,2 % vuodessa ja ylsi 237,26 M USD:een. Osakekohtainen tulos on laskenut 21,2 % vuodessa viimeisten 18 vuoden aikana. Vaxartn nettomarginaali 6,9 % on noussut verrattuna −7 900,2 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 16 967,05 %.
Vaxart osakekurssi
Vaxart liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Vaxart -osakkeesta
Vaxart Inc is a clinical-stage biotechnology company that specializes in the development of oral vaccines. The company's innovative business model focuses on the creation of oral recombinant vaccines, which are administered by pill rather than injection. Vaxart aims to revolutionize the way vaccines are delivered by providing a convenient and needle-free alternative. By leveraging their proprietary technology platform, the company can rapidly develop and produce vaccines for both infectious diseases and emerging public health threats. Vaxart's business model positions them as a leader in the development of oral vaccines, offering a promising solution to enhance global vaccination efforts.
Vaxart Inc is primarily active in the biotechnology and pharmaceutical industries.
Some of the main competitors of Vaxart Inc in the market are Moderna Inc, Pfizer Inc, Johnson & Johnson, Novavax Inc, and Inovio Pharmaceuticals Inc.
Vaxart Inc is a biotechnology company based in California, USA. Founded in 2004, they specialize in developing oral vaccines for a wide range of infectious diseases. Vaxart has made significant advancements in the field of immunization through their innovative platform, which enables the delivery of vaccines via tablets rather than injections. Their unique approach has gained recognition and partnerships with various organizations, including the US Department of Defense and National Institutes of Health. With a strong focus on developing effective and accessible vaccines, Vaxart Inc aims to make a positive impact on global healthcare.
Vaxart Inc has achieved significant milestones in its history. The company gained recognition for its innovative approach to vaccine development. One of the notable milestones includes the successful completion of Phase 2 clinical trials for their oral vaccine candidate, which demonstrated promising results. Vaxart Inc also entered into a collaboration agreement with a major pharmaceutical company to develop a potential universal flu vaccine. Additionally, the company received a grant from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of COVID-19 vaccine candidates. These milestones highlight Vaxart Inc's commitment to advancing immunization solutions and position it as a key player in the development of preventive healthcare.
Vaxart Inc is primarily present in the United States.
Vaxart Inc represents values of innovation, commitment, and growth. With a corporate philosophy focused on advancing groundbreaking oral vaccines, Vaxart aims to revolutionize the field of infectious diseases prevention. Through their proprietary oral tablet platform, the company strives to provide effective and accessible vaccine solutions globally. Vaxart Inc prides itself on its dedication to scientific excellence, aiming to deliver safe and convenient vaccines to address unmet medical needs. With a diverse and experienced team, Vaxart fosters a culture of collaboration and remains committed to driving positive changes in public health.
9 analyytikkoa arvioi tällä hetkellä Vaxart-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Vaxart-yhtiöltä 81,80 M USD liikevaihtoa ja −0,16 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Vaxart-osake noteerataan hintaan 0,39 EUR (0,43 USD).
Vaxart-osake (VXRT) on listattuna 3 pörssissä, muun muassa: NASDAQ (VXRT), Frankfurt (NB11.F), München (NB11.MU).
Vaxart Inc is a biopharmaceutical company that focuses on the development of oral vaccines and therapeutics. The company uses its proprietary technology platform to provide vaccines and therapeutics that have a broader impact and efficacy than conventional injectable vaccines. Vaxart's business model is based on the development of vaccines and therapeutics for human use. The company is working on the development of vaccines against a variety of infectious diseases such as influenza, Covid-19, and other respiratory diseases, as well as against chronic diseases such as cancer and HIV. Vaxart's technology platform enables rapid and cost-effective development of vaccine candidates and therapeutics, thereby enhancing the effectiveness of vaccines and therapeutics. Vaxart collaborates closely with government agencies, academic institutions, and other pharmaceutical manufacturers to advance research and development efforts and license its technology platform and products. The company has also developed a wide range of products based on its technology platform. Products of Vaxart include: - Oral Covid-19 vaccine: Vaxart has developed an oral Covid-19 vaccine that is currently being tested in clinical trials. The vaccine is based on the company's proprietary technology platform and is capable of providing broader immunity against Covid-19 than conventional injected vaccines. - Oral influenza vaccine: Vaxart has also developed an oral vaccine that is effective against influenza and is currently being tested in clinical trials. The vaccine is based on the company's proprietary technology platform and shows high efficacy in preclinical tests. - Oral HIV vaccine: Vaxart has also developed an oral HIV vaccine that demonstrates high efficacy in preclinical tests. The vaccine is based on the company's proprietary technology platform and is currently in clinical trials. - Oral RSV vaccine: Vaxart is working on the development of an oral vaccine against Respiratory Syncytial Virus (RSV). The vaccine is based on the company's proprietary technology platform and shows promising results in preclinical tests. - Oral HPV vaccine: Vaxart is also working on the development of an oral vaccine against Human Papillomavirus (HPV), which causes cervical cancer. The vaccine is based on the company's proprietary technology platform and is currently in preclinical tests. In summary, Vaxart Inc has a promising business model based on the development of oral vaccines and therapeutics. The company has successfully utilized its technology platform to bring a wide range of products to the market that can be used against infectious diseases and chronic conditions. With its promising pipeline, Vaxart has significant potential to fundamentally change and expand the vaccine and therapy market.
odotettu liikevaihto Vaxart on 81,80 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Vaxart on −36,38 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Vaxart:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,73. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Vaxart-osakkeen arvostusta.
Vaxart:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,21. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Vaxart-osakkeen arvostuskennuslukuna.
Vaxart:n Eulpool-laatuscore on 7/10.
Vaxart:n ISIN on US92243A2006. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Vaxart:n WKN on A2JD8X. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Vaxart:n ticker on VXRT. Tämä pörssinoteeraus käytetään Vaxart-osakkeiden kauppaan pörssissä.
Vaxart osake
Vaxart vertaisryhmä
Vaxart Ticker
Vaxart FIGI
Kaikki tunnusluvut ja syvällinen analyysi Vaxart:sta
Meidän osakeanalyysimme Vaxart-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Vaxart:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: